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Abstract
Background: The incidence and severity of tuberculosis chemotherapy toxicity is poorly characterised. We used
data available from patients in the REMoxTB trial to provide an assessment of the risks associated with the standard
regimen and two experimental regimens containing moxifloxacin.
Methods: All grade 3 & 4 adverse events (AEs) and their relationship to treatment for patients who had taken at
least one dose of therapy in the REMoxTB clinical trial were recorded. Univariable logistic regression was used to
test the relationship of baseline characteristics to the incidence of grade 3 & 4 AEs and significant characteristics (p
< 0.10) were incorporated into a multivariable model. The timing of AEs during therapy was analysed in standard
therapy and the experimental arms. Logistic regression was used to investigate the relationship between AEs (total
and related-only) and microbiological cure on treatment.
Results: In the standard therapy arm 57 (8.9%) of 639 patients experienced ≥1 related AEs with 80 of the total 113
related events (70.8%) occurring in the intensive phase of treatment. Both four-month experimental arms (“isoniazid
arm” with moxifloxacin substituted for ethambutol & “ethambutol arm” with moxifloxacin substituted for isoniazid)
had a lower total of related grade 3 & 4 AEs than standard therapy (63 & 65 vs 113 AEs). Female gender (adjOR 1.
97, 95% CI 0.91–1.83) and HIV-positive status (adjOR 3.33, 95% CI 1.55–7.14) were significantly associated with
experiencing ≥1 related AE (p < 0.05) on standard therapy. The most common adverse events on standard therapy
related to hepatobiliary, musculoskeletal and metabolic disorders. Patients who experienced ≥1 related AE were
more likely to fail treatment or relapse (adjOR 3.11, 95% CI 1.59–6.10, p < 0.001).
Conclusions: Most AEs considered related to standard therapy occurred in the intensive phase of treatment with
female patients and HIV-positive patients demonstrating a significantly higher risk of AEs during treatment. Almost
a tenth of standard therapy patients had a significant side effect, whereas both experimental arms recorded a lower
incidence of toxicity. That patients with one or more AE are more likely to fail treatment suggests that treatment
outcomes could be improved by identifying such patients through targeted monitoring.
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Background
Combination therapy for drug-susceptible tuberculosis
(TB) using isoniazid (H), rifampicin (R), pyrazinamide
(Z) and ethambutol (E) has been the standard of care for
several decades. While there is recognised toxicity asso-
ciated with some of the individual drugs (for example
hepatotoxicity [1], peripheral neuropathy [2], and gastro-
intestinal upset [3]) there are few prospective studies of
regimen-related toxicity [4–7]. Consequently, clinicians
treating tuberculosis largely rely on retrospective or an-
ecdotal evidence to guide their choices when patients
experience adverse events.
Previous reports include female gender, alcohol use, hu-
man immunodeficiency virus (HIV) infection and certain
ethnic groups [3–5, 8–11] as risk factors for experiencing
adverse events during therapy. Accurate definition of the
risk is confounded by the varying definitions of adverse
events or drug-related toxicity, and uncertainty of the re-
cording mechanism or its completeness. For example, eth-
ambutol related impairment of visual acuity rates vary
from 0.02% [12] and 9.4% [13] despite the importance of
the complication and the simplicity of its measurement.
To overcome the difficulties of biased reporting we
used the consistent adverse event reporting system used
in the REMoxTB trial [14] to investigate drug related
toxicity, as we believe that this is the most comprehen-
sive source of safety data for standard tuberculosis ther-
apy currently available. The aim of the paper was to
accurately characterise the patients at greatest risk, the
incidence and nature of the toxicity related to standard
TB therapy, and to investigate the impact of toxicity on
treatment outcomes. Additionally, the paper aimed to
compare the incidence of toxicity for standard TB ther-
apy and the two experimental arms in REMoxTB.
Methods
REMoxTB trial
The REMoxTB trial [14] was a double-blind,
placebo-controlled, randomised phase III trial to investigate
two experimental moxifloxacin (M)-containing treatment
regimens to treat pulmonary tuberculosis. There were 1931
patients randomised between 2007 and 2012 with 655
assigned to the “isoniazid arm” (2MHRZ/2MHR), 636
assigned to the “ethambutol arm” (2EMRZ/2MR), and 639
allocated to standard TB therapy as a control (2EHRZ/
4HR). Patients were followed for 18 months after random-
isation. We included all randomised patients in the
REMoxTB trial who had received at least one dose of their
allocated treatment.
Handling of safety data
Adverse events (AEs) were defined as any untoward med-
ical occurrence in a patient administered the trial medica-
tion (with or without a causal relationship to the drugs)
and were graded on a severity scale of 1 (least severe) to 4
(most severe) based on the Division of AIDS of the Na-
tional Institute of Allergy and Infectious Diseases criteria
[15]. The seriousness of an event (e.g. hospitalisation,
life-threatening, death) irrespective of the severity was de-
fined according to standard criteria. The local clinicians
made the relatedness assessment for each event and those
that were classified as “possibly”, “probably” or “definitely”
related to drug therapy were considered to be “related” for
the purposes of this analysis. Events that were assessed as
either “unlikely related” or “not related” were considered
to be “not related”. During the trial, sites were regularly
monitored for data collection, and serious AEs (SAEs)
were discussed in detail between the study medical moni-
tor and the local clinician before being discussed in a
safety board meeting with senior clinical specialists in the
trial consortium to ensure quality control. Analyses and
data handling were done using Stata statistical software
version 14.1 (StataCorp, Texas).
Baseline characteristics in standard therapy
Baseline characteristics for all the patients assigned to
standard therapy, and the characteristics for those patients
who experienced one or more related or unrelated grade
3/4 AE and those who experienced one or more related
grade 3/4 AE were tabulated. Univariable logistic regres-
sion was performed using each of the baseline characteris-
tics for patients receiving standard therapy in the table
against a binary outcome for experiencing one or more
total or related grade 3/4 AE. Those variables with a
p-value of < 0.10 were manually selected for inclusion in a
multivariable model, with age, gender and baseline weight
included regardless of univariable p value due to their
clinical relevance. Random-effects multivariable logistic
regression was used to test for associations between the
selected variables and grade 3/4 AEs with trial centre used
as the panel variable to account for any effect from the in-
dividual sites.
Adverse events in standard therapy over time
Incidence of grade 3/4 AEs and serious adverse events of
any severity grade (SAEs) by treatment phase of stand-
ard therapy were categorised based on the grade 3/4 AE
start date: intensive (weeks 0–8), continuation (weeks 9–
26), and follow-up (week 27-month 18 after randomisa-
tion). MedDRA coding for System Organ Class and Pre-
ferred Term was used to identify the most common
classes of adverse event. Patients were categorised based
on the number of grade 3/4 AEs experienced in each
phase of treatment. The mean number of SAEs per pa-
tient was calculated by dividing the total number of
SAEs by the total number of patients with one or more
SAE in each treatment phase. Patients who were with-
drawn or died in the previous treatment phase were not
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included in later phases in order to present an accurate
denominator for the number of patients at risk of an
event in each of the three treatment phases. To illustrate
the risk of grade 3/4 AE occurrence by time on standard
treatment we constructed an Epanechnikov kernel
smoothed hazard estimate with 95% confidence intervals
and plotted the hazard function on the y-axis and the
number of weeks from first dose on the x-axis.
Adverse events and treatment outcomes on standard
therapy
The number of grade 3/4 AEs reported by each patient tak-
ing standard therapy was related to their microbiological
outcome at 18 months after starting treatment. Patients
were scheduled for 8 weekly visits followed by 8 visits until
18 months after randomisation, and early morning and spot
sputum samples were to be collected (where possible) at
each visit. Sputum culture results were available for both
solid and liquid media in the trial database.
For this analysis, cure was defined as patients who
were culture negative at either 18 months or when they
were last reviewed in the trial with at least two consecu-
tive negative cultures on both solid and liquid media
prior to their final negative result. This outcome was
based exclusively on recorded culture status and was in-
dependent of the patient’s outcome in the original publi-
cation [14]. Patients were grouped according to whether
they had experienced ≥1 total or related grade 3/4 AE,
and the proportions of cured patients in these groups
were tabulated. The Chi square test was used to test for
significance and binary logistic regression with cure as
an outcome was used to test the association between ex-
periencing ≥1 total or related grade 3/4 AE and odds of
cure. Sex, age, baseline weight and HIV status were in-
cluded in a multivariable logistic model.
Adverse events in all treatment arms
The incidence and classification of grade 3 or 4 adverse
events (grade 3/4 AEs) and number of patients affected
were calculated across the treatment arms according to
the timing of the event: weeks 0–8 (EHRZ received on
standard arm; MHRZ on isoniazid arm; EMRZ on eth-
ambutol arm), weeks 9–17 (HR on standard arm; MHR
on isoniazid arm; MR on ethambutol arm), weeks 18–26
(HR on standard arm; placebo on both isoniazid and
ethambutol arms), and months 7–18 (no treatment ad-
ministered for any arm and in trial follow-up). Grade 3/
4 AEs were considered “clinically significant”. The pro-
portion of patients with one or more grade 3/4 AE was
compared across the treatment arms at each time win-
dow using the Chi square test. Time to first grade 3/4
AE in days after the first dose received was taken as the
event of interest and Kaplan-Meier curves were con-
structed to illustrate the timing of grade 3/4 AEs in the
three arms. The log rank test was used to compare the
time to event in the standard therapy arm against the
experimental arms individually.
Ethics approval and participant consent
The REMoxTB study was carried out with approval
from the ethics board at University College London,
and this included approval for the use of data and
samples collected in other studies to improve the
diagnosis and treatment of tuberculosis. All rando-
mised patients agreed to any data and samples col-
lected as part of the trial being used in further
studies to improve the diagnosis and treatment of
tuberculosis, as stated on the informed consent form
for the study. All the research activities and data
collection for the study was compliant with the
Helsinki Declaration and the principles of Good
Clinical Practice.
Results
Baseline characteristics for patients allocated to standard
therapy
Of 639 patients taking standard therapy 57 (8.9%) expe-
rienced one or more grade 3/4 AEs judged to be related
to their treatment, compared to 45 (6.9%) of 655 in the
isoniazid and 40 (6.3%) of 636 in the ethambutol arm (p
= 0.21, see Tables 1 and 5). Baseline weight as a categor-
ical variable (OR 0.79, 95% CI 0.65–0.97), female sex
(OR 1.60, 95% CI 1.06–2.39), and HIV infection (OR
3.45, 95% CI 1.86–6.42) were significantly associated
with ≥1 grade 3/4 AE in univariable logistic regression.
However, only HIV infection was significantly associated
with experiencing any grade 3 or 4 AE in a multivariable
model (adjOR 3.43, 95% CI 1.82–6.49). Female sex
(adjOR 1.97, 95% CI 0.91–1.83) and HIV infection
(adjOR 3.33, 95% CI 1.55–7.14) were significantly associ-
ated with grade 3/4 AEs considered related to standard
therapy after being selected for inclusion in the multivar-
iable model (both p values < 0.05, see Table 2).
Adverse events in standard therapy
Among the 113 related grade 3/4 AEs in the standard
therapy group 80 (70.8%) were reported in the intensive
phase of treatment (month 1 &2) as shown in Table 3
and illustrated in Fig. 1. Of the 57 patients who experi-
enced ≥1 related grade 3/4 AE on treatment, 47 (82.5%)
experienced an event in the intensive phase. The related
adverse events most commonly reported were elevated
liver enzymes (38 of 38 “hepatobiliary” events), arthralgia
(15 of 22 “musculoskeletal” events), and diabetic compli-
cations (4 of 12 events attributed to “metabolism &
nutrition”) (see Table 3). There was one case of deterior-
ation in visual acuity reported in the standard arm (data
not shown).
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While the majority of SAEs were reported during ther-
apy 10 of the 16 deaths in this treatment arm occurred
after treatment was completed (see Table 3). The most
common causes of death were trauma, suicide or un-
known cause but presumed to be violent (8 of 16), and
related to TB disease (3 of 16). Right heart failure, sepsis
of unknown origin, and uncontrolled hypertension
accounted for the remaining three deaths. None of the
deaths in the standard therapy group were assessed as
related to treatment.
Treatment outcomes for patients on standard therapy
Patients who had one or more total or related grade 3/4
AE were less likely to achieve microbiological cure com-
pared to patients who did not experience a grade 3/4 AE
(see Table 4). Of patients taking standard TB therapy,
21.1% (27 of 128) of patients with ≥1 grade 3/4 AE were
not cured, compared to 9.2% (47 of 511) of patients who
did not experience any grade 3/4 AE. Similarly, 26.3%
(15 of 57) of patients who experienced ≥1 grade 3/4 AE
considered related to treatment did not achieve cure
Table 1 Baseline characteristics of patients in the standard therapy arm
Total ≥1 Grade 3/4 AEs ≥1 Related Grade 3/4 AEs
No of subjects 639 128 57
(% total) (20.0%) (8.9%)
Gender (%)
Male 447 79 (17.7%) 31 (6.9%)
Female 192 49 (25.5%) 26 (13.5%)
Age
<25yrs 187 37 (19.8%) 11 (5.9%)
25–35yrs 184 29 (15.8%) 20 (10.9%)
>35yrs 268 62 (23.1%) 26 (9.7%)
Baseline Weight
<40kg 63 18 (28.6%) 8 (12.7%)
40–45kg 103 29 (28.2%) 14 (13.6%)
>45–55kg 254 40 (19.7%) 13 (5.1%)
>55–75kg 203 40 (19.7%) 22 (10.8%)
>75kg 16 1 (6.2%) 0 (0.0%)
Median 51.0 48.3 49.0
(IQR) (45.0–57.7) (42.3–57.0) (42.5–58.0)
Ethnicity (%)
Black 295 58 (19.7%) 26 (8.8%)
Asian 194 47 (24.2%) 20 (10.3%)
Mixed Race 140 21 (15.0%) 9 (6.4%)
Other 10 2 (20.0%) 2 (20.0%)
Smoking Hist (%)
Never 298 63 (21.1%) 27 (9.1%)
Ex-smoker 155 29 (18.7%) 16 (10.3%)
Current 186 36 (19.3%) 57 (7.5%)
HIV Status
Positive 46 20 (43.5%) 11 (23.9%)
Negative 593 108 (18.2%) 46 (7.8%)
Median CD4+ (IQR) 365.5 (307.0–456.0) 317.5 (267.5–458.5) 340.0 (267.0–488.0)
Cavities on CXR (%) 456 90 (19.7%) 32 (7.0%)
MGIT Median TTP (IQR) 114 (88–156) 111 (86–163) 118 (95–173)
The baseline characteristics for all patients in the treatment arm are listed along with the baseline characteristics for patients who experienced one or more grade
3 & 4 adverse event related or unrelated. Patients who experienced one or more grade 3 or 4 related adverse event are listed separately. Row percentages are
included for each characteristic to show proportions of the total who experienced one or more adverse events
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compared to 10.1% (59 of 582) of patients who did not
experience a related grade 3/4 AE (p value < 0.001).
Experiencing ≥1 related or unrelated grade 3/4 AE was
significantly associated with not being cured of TB in a
multivariable logistic regression model (adjOR 2.60, 95%
CI 1.52–4.46, p < 0.001). A similar relationship was seen
between ≥1 related-only grade 3/4 AE and an outcome
of not cured (adjOR 3.11, 95% CI 1.59–6.10, p value <
0.001). The multivariable model included sex, age and
baseline weight (clinical significance) and HIV status
(due to earlier reported association with AE incidence).
Adverse events across all treatment arms over time
Most grade 3/4 AEs occurred during the intensive phase
for all regimens (see Table 5) with 80 (73.4%), 51 (81.0%)
and 44 (67.7%) related grade 3/4 AEs during the intensive
phase in the standard, isoniazid, and ethambutol arms re-
spectively. Both experimental arms had lower numbers of
related grade 3/4 AEs (64 and 66 in the isoniazid and eth-
ambutol arms vs 113 during standard therapy). There was
a significant difference in the proportion of patients ex-
periencing ≥1 related grade 3/4 AE in the intensive phase
(p value 0.03) with the smallest proportion in the etham-
butol arm (25 of 636 [3.9%], see Table 5). In all treatment
arms the most common type of related grade 3/4 AEs
were “hepatobiliary disorders” (40.7% in standard therapy,
and 42.2% & 37.9% in isoniazid & ethambutol arms).
There was no difference in either the overall total or
related total of grade 3/4 AEs between the three treat-
ment arms during weeks 18–26 when patients in the ex-
perimental regimens were receiving placebo. The Kaplan
Meier curves in Fig. 2 illustrate the majority of events
Table 2 Logistic Regression output to test the association between baseline characteristics and the risk of experiencing one or
more grade 3 or 4 Adverse Event (AE) on standard TB therapy
Univariable analysis Multivariable analysis
Baseline characteristic OR 95% CI P value adjOR 95% CI P value
Female sex 1.60 1.06–2.39 0.02 1.36 0.87–2.13 0.18
(2.10) (1.21–3.65) (0.01) (1.97) (0.91–1.83) (0.03)
Age 1.13 0.90–1.43 0.30 1.15 0.90–1.47 0.25
(1.25) (0.89–1.74) (0.20) (1.29) (0.91–1.83) (0.16)
Baseline weight 0.79 0.65–0.97 0.02 0.80 0.63–1.03 0.08
(0.86) (0.65–1.14) (0.30) (0.90) (0.67–1.21) (0.49)
Ethnicity
Black Reference *** *** *** *** ***
Asian 1.31 0.84–2.02 0.23 *** *** ***
(1.19) (0.64–2.20) (0.58)
Mix race 0.72 0.42–1.24 0.24 *** *** ***
(0.71) (0.32–1.56) (0.40)
Smoking Hist.
Never Reference *** *** *** *** ***
Ex-smoker 0.86 0.53–1.40 0.54 *** *** ***
(1.16) (0.60–2.22) (0.66)
Current 0.90 0.57–1.42 0.64 *** *** ***
(0.82) (0.42–1.60) (0.56)
HIV positive 3.45 1.86–6.42 < 0.001 3.43 1.82–6.49 < 0.01
(3.74) (1.78–7.84) (< 0.001) (3.33) (1.55–7.14) (< 0.01)
Cavities on CXR 1.03 0.62–1.71 0.92 *** *** ***
(0.62) (0.31–1.21) (0.16)
Baseline TTP 1.24 0.55–2.82 0.60 *** *** ***
(1.39) (0.47–4.09) (0.55)
Univariable odds ratio (OR) shown and characteristics with p value < 0.10 were manually added to a multivariable model to test for association. A random-effects
multivariable logistic regression model was used with trial centre as the panels. ORs for experiencing any grade 3 or 4 AE shown with ORs for experiencing one or
more related grade 3 or 4 AE provided in brackets. Baseline variables indicated in the table where necessary. Age and weight were entered as categorical
variables shown in Table 2, and baseline time to MGIT positive (TTP) was entered as binary variable of below or above/equal to the median. Age, gender and
baseline weight were included in the multivariable model regardless of p value due to clinical significance
***No analysis performed
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occurring in the intensive phase followed by a plateau
from approximately 9 weeks after starting treatment (log
rank p = 0.19 for comparing standard therapy and isonia-
zid arm; p = 0.07 for standard therapy and ethambutol
arm). The drop seen at 8 weeks of treatment in the num-
ber of patients at risk was driven by one site reporting 40
grade 3/4 AEs (30 considered related) from all treatment
arms in a 30-week time window of the trial between May
and December 2010 (the site reported a total of 146 grade
3/4 AEs). 36 of 40 (90%) of these events were reported in
the intensive phase of the patient’s treatment.
Discussion
In a study encompassing a large number of drug-sensitive
TB patients from across the world there is evidence that
almost a tenth of patients experienced serious side effects
due to their TB medication. The existing literature quotes
a rate of approximately 5–20% for significant toxicity from
standard TB therapy [5, 9, 16–21] and hepatotoxicity is
the most frequently detected [1, 22, 23]. The liver enzyme
profile on treatment for standard TB therapy and the ex-
perimental arms in REMoxTB has been described in more
detail elsewhere [24]. As the exclusion criteria removed
those with severe disease or concomitant diseases, our es-
timate must be considered a minimum [14], however the
follow-up period was comparable to two other recent
large tuberculosis trials [25, 26].
We observed that most of the AEs in standard therapy
occurred in the intensive phase. The explanation for this
is uncertain, and could involve a degree of survivorship
bias or increased tolerance of side effects, but may relate
to the presence of pyrazinamide in all three regimens. Pyr-
azinamide is a drug with a well-recognised toxicity profile
[11], while ethambutol (the other drug only present for
Table 3 Events in standard arm by treatment phase
Intensive phase
(Month 0–2)
n = 639
Continuation phase
(Month 3–6)
n = 596
Follow Up phase
(Month 7–18)
n = 569
Total Grade 3 & 4 AEs Reported 135 62 53
Related 80 29 4
(% Total) (59.3%) (46.8%) (7.5%)
No of Grade 3 AEs Reported 100 48 33
Related 50 23 3
(%Grade3) (50.0%) (57.5%) (9.1%)
No. Grade 4 AEs Reported 35 14 20
Related 30 6 1
(%Grade4) (85.7%) (42.9%) (5.0%)
System Organ Class of Related Events*
Hepatobiliary 25 13 0
Musculoskeletal 15 7 0
Metabolism & Nutrition 9 1 2
Blood & Lymphatic 5 2 1
No of Related Grade 3 or 4 AEs per Patient
0 592 581 566
1 33 12 2
2 10 1 1
≥ 3 4 2 0
No of Patients with≥ 1 SAE (% n) 32 (5.0%) 18 (3.0%) 20 (3.5%)
No of Patients with ≥ 1 Related SAE (%n) 17 (2.7%) 3 (0.5%) 2 (0.4%)
Mean No of SAEs per Patient 1.78 1.39 1.60
No of Withdrawals 38 26 1
No of Deaths 5 1 10
The number of grade 3 & 4 adverse events (total and related only) recorded in each treatment arm are shown with percentage of the total number of similar
events across all treatment phases. Most common System Organ Classes for grade 3 & 4 adverse events are tabulated by treatment phase, along with tallies of
patients in each phase split by the number of grade 3 or 4 adverse events experienced in the treatment phase. Serious adverse events in each phase are also
shown, regardless of their severity grading. The denominator for each treatment phase was determined by subtracting the number of withdrawals and deaths
from the denominator in the previous phase. The treatment phases were not independent and the same patient could appear in all three of the phases. *Note
that some events excluded because of undocumented onset date
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the intensive phase) has few reported side effects [27].
Additionally, hepatotoxicity and arthralgia were among
the most common events and these are frequently re-
ported side effects of pyrazinamide [28, 29]. The sterilising
activity of pyrazinamide makes it an essential component
of standard therapy [30], but there is still some uncertainty
surrounding its ideal dosing [31] and there is evidence of
a dose-response relationship with toxicity [32]. There is a
pressing need to direct more research to optimise the
most effective and least toxic dose alongside the other
components of the standard regimen [33].
It is perhaps significant there was little difference in the
number of related AEs in months 5 and 6 between those
receiving active treatment and those on placebo. This
could emphasise the importance of TB induced pathology
on the presence and reporting of significant medical
events. Reducing toxicity associated with medication is
one of the factors driving the development of shorter
treatment regimens for TB [34], however this finding sug-
gests that concerns about toxicity may not be as important
as previously thought. While the experimental arms were
less toxic, it should be noted that they were also less ef-
fective. It was notable that both experimental regimens
were less toxic and both of these reduced the bacterial
load more quickly than standard regimen [14]. Whether
there is a causal relationship between these observations is
not known. This means, perhaps, that the motivation for
shortening treatment needs to focus around patient ac-
ceptability and logistical benefits of few doses, visits to
clinics and enhanced adherence.
We found female patients and HIV-positive patients to be
at significantly higher risk of toxicity. Existing guidelines
acknowledge the issues surrounding TB-HIV co-infection
[35, 36], but these do not reference female gender as a risk
factor for a more complicated treatment course (outside of
pregnancy). It is unclear if reporting bias has played a role in
AE recording for the trial, as there have been discrepancies
noted between the genders in regards to healthcare-seeking
behaviour previously [37, 38]. Nonetheless, clinicians should
consider closer monitoring of both HIV-positive and female
patients taking HRZE, especially in the intensive phase of
treatment.
Fig. 1 Hazard Curve for Related Grade 3 & 4 Adverse Events. Hazard Curve for Grade 3 or 4 Related Adverse Events According to Number of
Weeks Since First Dose of Standard Therapy. Hazard function for the occurrence of a grade 3 or 4 related adverse event (with 95% confidence
intervals) is plotted on the y axis, with the number of weeks following the first dose of standard tuberculosis therapy on the x axis. The rise in the
hazard function after week 25 is accounted for by 2 events reported as “possibly” related to study drug
Table 4 Rates of microbiological cure according to number of Grade 3 or 4 adverse events experienced by patients taking standard
TB therapy
No. of grade 3/4 AEs Microbiological cure No microbiological cure Total
Total 0 464 (90.8%) 47 (9.2%) 511
≥1 101 (78.9%) 27 (21.1%) 128
Related only 0 523 (89.9%) 59 (10.1%) 582
≥1 42 (73.7%) 15 (26.3%) 57
Patients are grouped by the number of AEs they experienced in the trial. The number of patients who were either cured or not cured of their TB (based on
definition given in Methods section) are displayed with row percentages (Chi square test p value < 0.001)
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Table 5 Comparing adverse events in treatment arms
Standard Arm
(2EHRZ/4HR)
n = 639
Isoniazid Arm
(2MHRZ/2MHR)
n = 655
Ethambutol Arm
(2EMRZ/2MR)
n = 636
P value
Intensive Phase
(Weeks 0–8)
Patients with≥ 1
Grade 3/4 AEs
(Tot No AEs)
85 (135) 83 (119) 66 (114) 0.24
Patients with≥ 1
Related Grade 3/4
AEs (Tot No AEs)
47 (80) 36 (51) 25 (44) 0.03
Continuation Phase
(Weeks 9–17)
Patients with≥ 1
Grade 3/4 AEs
(Tot No AEs)
29 (47) 25 (32) 26 (37) 0.81
Patients with≥ 1
Related Grade 3/4
AEs (Tot No AEs)
14 (27) 9 (9) 16 (19) 0.32
Continuation/Placebo
Phase (Weeks 18–26)
Patients with≥ 1
Grade 3/4 AEs
(Tot No AEs)
12 (15) 13 (17) 17 (21) 0.57
Patients with≥ 1
Related Grade 3/4
AEs (Tot No AEs)
2 (2) 3 (3) 2 (2) 0.88
Total* Patients with≥ 1
Grade 3/4 AEs (≥1
Related Grade 3/4 AEs)
128 (57) 103 (45) 94 (40) 0.40 (0.21)
Total Grade 3/4 AEs
(Related Grade 3/4 AEs only)
250 (113) 217 (64) 209 (66)
The number of patients experiencing one or more grade 3 or 4 adverse event, and those who experienced events considered related to treatment only, are shown
according to the treatment phase and study arm in the trial. The numbers of events are shown in brackets. The Chi square test was used to test for significant
differences between the treatment arms for the proportions of patients who experienced ≥1 event in each treatment phase, for both total and related-only grade 3 or 4
AEs. Number of patients shown is number for that treatment window: 4 patients with ≥1 related AE appear in more than one time window on standard therapy, and 3
patients in both the isoniazid and ethambutol arms. Additionally, two patients excluded from the total count on the standard arm as no start date for AEs recorded
*AEs that occurred in the follow-up phase (months 7–18) included in total
Fig. 2 Related Grade 3 or 4 Adverse Events By Treatment Arm. Kaplan Meier Curves for Time to First Event for Related Grade 3 or 4 Adverse
Events in the Treatment Arms. The time to first event is plotted for all the patients at risk in the standard (blue), isoniazid (red) and ethambutol
(green) arms. The y axis plots the proportion of the patients still at risk, and the risk table presents this numerically. The data was censored at
200 days after the first dose for all three arms, and there was no significant difference between the isoniazid arm (p = 0.19) or the ethambutol
arm (p = 0.07) when compared to the standard therapy using the log rank test
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Those patients reporting one or more related grade 3/
4 AE were more likely to fail to achieve sustained spu-
tum culture negative status. This is an important obser-
vation and emphasises the need to detect toxicity early
and manage it properly. The reasons for this difference
in outcome is uncertain and would merit further investi-
gation in prospective studies. It may be that better man-
agement of drug toxicity in tuberculosis treatment could
deliver better outcomes.
It is notable that the majority of deaths occurred after
completing treatment and were unrelated to trial medi-
cation, emphasising the importance of social context of
TB infection. It may be that this is due to other under-
lying conditions that also contribute to a poor outcome
or that experiencing toxicity reduces adherence to ther-
apy. This relationship may explain why the cure rate
with standard therapy for drug-sensitive disease can be
as low as 80% in real-world settings [39].
This study is limited by innate reporting bias and reli-
ance on a subjective assessment of severity in many
cases (for example, pain scores). An example of this is
the reporting activity at one site in the trial. After a trial
pause this site reported almost one third of its total
grade 3/4 AEs, and assessed 75% of them as being re-
lated to treatment in a 30 week period. Attributing caus-
ality to AEs has been shown to produce unreliable and
subjective data [40] and caution has been advised when
using trial data to evaluate drug safety profiles [41].
Given the proximity of the recent pause in trial recruit-
ment it could be that there was concern over the safety
of the experimental regimens and that in a double-blind
trial this translated into a lower threshold to both report
events and to attribute causality to the drugs.
While there is still merit in using AEs to investigate
drug safety profiles, the often subjective nature of the
reporting is a limitation. We are also aware of the poten-
tial dangers of drawing conclusions based on relatedness
assessments for AEs [40, 42] and to this end have pre-
sented both total and related AEs in the analysis. Over-
all, the careful and consistent way in which data were
recorded for this large number of patients does mean,
however, that we are able to generate important observa-
tions and suggest future research.
In this paper we have shown that most adverse events
occur in the intensive phase of treatment with female
patients and those who are HIV positive constituting a
demographic that should be closely monitored for tox-
icity. We have also found that those who experience
clinically significant drug related-toxicity while taking
standard TB therapy are at greater risk of failing treat-
ment. From this we conclude that we need to improve
our methods of detecting and managing patients experi-
encing toxicity, and that there is real need for novel
drugs with more favourable toxicity profiles. Our data
provide an evidence base to plan future research and to
support improved treatment guidelines. Tuberculosis re-
mains a global health threat, predominantly affecting a
vulnerable and disadvantaged population, and this paper
illustrates the need for clinicians to be quick to respond
to side effects from treatment to ensure their patients
have the best chance of achieving a cure.
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